Publications by authors named "Timothy Guzi"

Claim this Profile
H
Human polymerase θ helicase positions DNA microhomologies for double-strand break repair.
Christopher J Zerio, Yonghong Bai, Brian A Sosa-Alvarado, Timothy Guzi, Gabriel C Lander

Nat Struct Mol Biol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Alison J Davis, Natasja Brooijmans, Jason D Brubaker, Faith Stevison, Timothy P LaBranche, Timothy J Guzi

Sci Transl Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human polymerase theta helicase positions DNA microhomologies for double-strand break repair.
Christopher J Zerio, Yonghong Bai, Brian A Sosa-Alvarado, Timothy Guzi, Gabriel C Lander

bioRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.
Stefanie S Schalm, Erin O'Hearn, Kevin Wilson, Timothy P LaBranche, Grace Silva, Timothy Guzi

Gastro Hep Adv· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
Meredith S Eno, Jason D Brubaker, John E Campbell, Chris De Savi, Timothy J Guzi

J Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
Yuan Tian, Brian R Lahue, Yao Ma, Latha G Nair, Weidong Pan, Timothy Guzi

Bioorg Med Chem Lett· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Megan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, Emily Rozsahegyi, Nooreen Rubin, Timothy Guzi

Cancer Discov· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.
Joey L Methot, Hua Zhou, Sam D Kattar, Meredeth A McGowan, Kevin Wilson, Timothy Guzi

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Targeted Therapy with BLU-667 for -Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Timothy Guzi

Cancer Discov· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A precision therapy against cancers driven by mutations.
Erica K Evans, Alexandra K Gardino, Joseph L Kim, Brian L Hodous, Adam Shutes, Timothy Guzi

Sci Transl Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Margit Hagel, Chandra Miduturu, Michael Sheets, Nooreen Rubin, Weifan Weng, Timothy Guzi

Cancer Discov· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
Yao Ma, Brian R Lahue, Craig R Gibeau, Gerald W Shipps, Stéphane L Bogen, Timothy J Guzi

ACS Med Chem Lett· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Marc A Labroli, Michael P Dwyer, Ruichao Shen, Janeta Popovici-Muller, Qinglin Pu, Timothy J Guzi

Bioorg Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
Michael P Dwyer, Kartik Keertikar, Kamil Paruch, Carmen Alvarez, Marc Labroli, Timothy J Guzi

Bioorg Med Chem Lett· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Timothy J Guzi, Kamil Paruch, Michael P Dwyer, Marc Labroli, Frances Shanahan

Mol Cancer Ther· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
Marc Labroli, Kamil Paruch, Michael P Dwyer, Carmen Alvarez, Kartik Keertikar, Timothy J Guzi

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Michael P Dwyer, Kamil Paruch, Marc Labroli, Carmen Alvarez, Kerry M Keertikar, Timothy J Guzi

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Lianyun Zhao, Yingxin Zhang, Chaoyang Dai, Timothy Guzi, Derek Wiswell

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase.
Lorena Taricani, Frances Shanahan, Rob H Pierce, Timothy J Guzi, David Parry

Cell Cycle· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
David Parry, Timothy Guzi, Frances Shanahan, Nicole Davis, Deepa Prabhavalkar

Mol Cancer Ther· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.
Kamil Paruch, Michael P Dwyer, Carmen Alvarez, Courtney Brown, Tin-Yau Chan, Timothy J Guzi

ACS Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided discovery of cyclin-dependent kinase inhibitors.
Thierry O Fischmann, Alan Hruza, José S Duca, Lata Ramanathan, Todd Mayhood, Timothy J Guzi

Biopolymers· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Michael P Dwyer, Kamil Paruch, Carmen Alvarez, Ronald J Doll, Kerry Keertikar, Timothy J Guzi

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
Kamil Paruch, Michael P Dwyer, Carmen Alvarez, Courtney Brown, Tin-Yau Chan, Timothy J Guzi

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYC-202 Cyclacel.
Timothy Guzi

Curr Opin Investig Drugs· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis